Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash & Current Investments (2016 - 2026)

Lexaria Bioscience's Cash & Current Investments history spans 12 years, with the latest figure at $5.1 million for Q1 2026.

  • Quarterly results put Cash & Current Investments at $5.1 million for Q1 2026, down 21.62% from a year ago — trailing twelve months through Feb 2026 was $5.1 million (down 21.62% YoY), and the annual figure for FY2025 was $1.9 million, down 70.07%.
  • Cash & Current Investments for Q1 2026 was $5.1 million at Lexaria Bioscience, up from $4.3 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $8.9 million in Q1 2022 to a low of $1.5 million in Q3 2023.
  • The 5-year median for Cash & Current Investments is $4.8 million (2022), against an average of $5.2 million.
  • The sharpest move saw Cash & Current Investments tumbled 76.01% in 2023, then skyrocketed 339.85% in 2024.
  • Year by year, Cash & Current Investments stood at $4.8 million in 2022, then plummeted by 57.8% to $2.0 million in 2023, then skyrocketed by 300.58% to $8.1 million in 2024, then tumbled by 47.26% to $4.3 million in 2025, then grew by 19.78% to $5.1 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $5.1 million, $4.3 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.